Luye Pharma GroupFRA:LUP +3.03%47 EBITDA Margin % is 40.50% as of Dec. 2025, which is 11% above its 10-year median of 36.65. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 954 Drug Manufacturers companies, Luye Pharma Group ranks better than 93.19% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Luye Pharma Group's EBITDA for the
six
months ended in Dec. 2025 was €153.6 Mil. Luye Pharma Group's Revenue for the
six
months ended in Dec. 2025 was €379.2 Mil. Therefore, Luye Pharma Group's EBITDA margin for the quarter that ended in Dec. 2025 was 40.50%.
Luye Pharma Group (FRA:LUP) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Luye Pharma Group EBITDA Margin % Related Terms
Luye Pharma Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a EBITDA Margin % of 40.50% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Luye Pharma Group and its competitors. This is 11% above median its historical median of 36.65. Over the past decade, Luye Pharma Group's EBITDA Margin % has ranged from 17.44 to 39.28. According to the industry distribution chart, Luye Pharma Group ranks #65 out of 954 companies in the Drug Manufacturers industry, placing it in the top 6.8%.
Is Luye Pharma Group's EBITDA Margin % too high?
Luye Pharma Group's current EBITDA Margin % of 40.50% is 11% above median its 10-year median of 36.65. Over the past 10 years, this metric has ranged from a low of 17.44 to a high of 39.28. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Luye Pharma Group's value of 40.50% is 223.6% above this industry median. Based on the distribution chart, Luye Pharma Group ranks #65 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #65 out of 954 companies for EBITDA Margin %. This places Luye Pharma Group in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.52. Luye Pharma Group's value of 40.50% is 223.6% above this benchmark. Historically, Luye Pharma Group's own EBITDA Margin % has ranged from 17.44 to 39.28 over the past decade. While the company's 10-year median is 36.65 vs. the industry median of 12.52, Luye Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current EBITDA Margin % of 40.50% is 223.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current EBITDA Margin % is 40.50%, which is 11% above median its own 10-year median of 36.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current EBITDA Margin % is 40.50%, which is 11% above median its 10-year median of 36.65 and 223.6% above the Drug Manufacturers industry median of 12.52. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current EBITDA Margin % is 40.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
EBITDA Margin %: 40.50% (11% above median its 10-year median of 36.65)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
Industry Position: 223.6% above the Drug Manufacturers median (#65 of 954)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
